AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01234311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasquinimod
Description: Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
Study NCT01234311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02116738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flap Transposition Procedures
Description: Modified Limberg Flap Transposition Procedure and Lateral Advancement Flap Transposition with Burrow's Triangle Procedure in The treatment of Pilonidal Sinus Diseases
Study NCT03948594 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resource
Description: 1 packet resource(237ml), 1.05kcal/ml, 53.6g carbohydrate and 9g protein
Study NCT03948594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: plain water
Description: 250ml plain water
Study NCT01877811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXDX-105
Description: During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment.
Study NCT04741295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.
Study NCT04506281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant treatment
Description: PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
Study NCT02321397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Study NCT02321397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: Prolonged Release Tablets
Study NCT02061904 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: DEXA: dual energy X-ray absorptiometry
Description: Bone mineral density development measured with dual energy X-ray absorptiometry
Study NCT02061904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Short Form Health Survey 12
Description: questionnaire for general health monitoring
Study NCT02061904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VAS-satisfaction
Description: questionnaire for intervention satisfaction monitoring
Study NCT02061904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VAS-pain
Description: questionnaire for pain monitoring
Study NCT02061904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Harris Hip Score
Description: questionnaire for hip function monitoring
Study NCT00880100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrase® MT12
Description: Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
Study NCT04104841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally Enhancing Adolescents' Mood in Schools
Description: 8-session modified behavioral activation intervention
Study NCT04104841 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Referral to school mental health provider, social worker, or community care.
Study NCT03929406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Tissue Imprint
Description: Brain Tissue Imprint procedure (BTI) is performed during DBS surgery. Before the implantation of the electrode, the surgeon uses a dilator. It is a rigid stylet with a blunt end, intended to prepare the way for the final electrode. This dilator is lowered gently through the cerebral parenchyma up to the target then removed to be replaced by the electrode.~In our BTI study, the standard dilator used in DBS surgery will be replaced by a CE marked Medical Device. This brain imprint kit will be used for each hemisphere. The procedure is the following:~* The guide tube with the first stylet is set up to the target~* Withdrawal of the first stylet and insertion of the second stylet for one minute to have a spontaneous and adequate tissue adhesion~* Withdrawal of the guide tube containing the stylet. This last step will prevent contamination of the harvested material on the stylet during the removal.
Study NCT03021590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500Mg Oral Tablet
Description: Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all~,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth
Study NCT03021590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500Mg Oral Tablet
Description: Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
Study NCT03275116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 'Respimat' 5 mcg
Description: Once daily single bronchodilation
Study NCT03275116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclidinium Bromide/Formoterol Fumarate 340/12 mcg
Description: Twice daily dual bronchodilation
Study NCT03468075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle
Study NCT03468075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered on Days 1, 8 and 15, after the infusion of ascorbate
Study NCT04697836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ST
Description: After a computer-generated randomization list with a 1:1 intergroup ratio, ensuring equal distribution in the two groups, 30 opaque sealed envelopes numbered 1-30 were prepared. The patients were randomly divided into the Group with bilateral CPB with 15 ml 0.5% bupivacaine or the patients with translaryngeal block with 5 ml 2% lidocaine in addition to bilateral CPB.~Following inclusion, two research assistants, with no further involvement in the study, prepared 15mL syringes and 5 ml syringes according to the envelope's specifications. The syringes were marked with the patient's randomization number. All other investigators, staff, and patients were blinded to group allocations. Before surgery, the patients were transferred to the specified block room area monitored with 3-lead electrocardiography, pulse oximetry, and non-invasive blood pressure. All patients had two intravenous cannula lines, and then bilateral CPB block procedures were performed in awake non-sedated patients.
Study NCT04697836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ST
Description: After a computer-generated randomization list with a 1:1 intergroup ratio, ensuring equal distribution in the two groups, 30 opaque sealed envelopes numbered 1-30 were prepared. The patients were randomly divided into the Group with bilateral CPB with 15 ml 0.5% bupivacaine or the patients with translaryngeal block with 5 ml 2% lidocaine in addition to bilateral CPB.~Following inclusion, two research assistants, with no further involvement in the study, prepared 15mL syringes and 5 ml syringes according to the envelope's specifications. The syringes were marked with the patient's randomization number. All other investigators, staff, and patients were blinded to group allocations. Before surgery, the patients were transferred to the specified block room area monitored with 3-lead electrocardiography, pulse oximetry, and non-invasive blood pressure. All patients had two intravenous cannula lines, and then bilateral CPB block procedures were performed in awake non-sedated patients.
Study NCT03210714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT00085358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given intraperitoneally
Study NCT00085358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV or intraperitoneally
Study NCT00085358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00085358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT02690389 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Flumazenil
Description: used alone or with acupuncture
Study NCT02690389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Description: used alone or with acupuncture
Study NCT02690389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: used alone or with flumazenil
Study NCT03907592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Description: Supplementation of 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout the study period.
Study NCT03907592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Description: Supplementation of 4000 mg L-leucine per day throughout the study period.
Study NCT03907592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training at the gym, twice a week for 24 weeks (48 training units in total).
Study NCT05423704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Description: Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
Study NCT02005510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed in-home high-risk HPV testing kit
Study NCT02005510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Study NCT02005510 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Study NCT04151446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Scleral Microporation
Description: Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
Study NCT03210714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo a bone marrow aspiration and/or biopsy
Study NCT03210714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo a bone scan
Study NCT03210714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT03210714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study NCT03210714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03210714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03210714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03210714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan
Study NCT03210714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo radionuclide imaging
Study NCT03210714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study NCT01977807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proscan, Zyoptix and Supracor
Description: One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
Study NCT03382262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Extended-release 32 mg FX006 IA injection
Study NCT03382262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAcs 40 mg
Description: Immediate-release 40mg TAcs IA injection
Study NCT02578992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head-lift position
Description: A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
Study NCT02578992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7cm high pillow
Description: A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
Study NCT01413828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent
Description: Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
Study NCT01413828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequential
Description: Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
Study NCT03338036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback
Description: HRV biofeedback constitutes initial training with the android device and application, and HRV training performed at home. This training will occur twice daily, and each session will take five minutes.
Study NCT03338036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: LORETA Z-Score neurofeedback training will occur three times per week with a trained study investigator.
Study NCT02599857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONCOR smartphone application
Study NCT03062267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Interventionist
Description: A mobile interventionist is a trained clinician who provides supportive messaging through text messages via mobile devices (i.e. basic / smartphones)
Study NCT02233582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
Study NCT02233582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Study NCT00903994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketoprofen Topical Patch 20%
Description: Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
Study NCT03105245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy (ECT) time interval + Anaesthetic (Thiopentone)
Description: The intervention in this study is the time interval between anaesthetic administration and ECT stimulus
Study NCT03384212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Study NCT03384212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Study NCT03384212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Study NCT03384212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT03384212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Study NCT02512588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTD-001
Study NCT02512588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03602144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Description: Participants will receive a carbohydrate-based breakfast beverage everyone morning for 42 days.
Study NCT02340572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRS-080#022-DP
Description: hepcidin antagonist
Study NCT02340572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRS-080-Placebo#001
Description: Placebo treatment
Study NCT02360449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Initiation Motivation Intervention
Description: The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
Study NCT02157584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: 2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
Study NCT02157584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: 2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
Study NCT03978572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Exercise intervention designed to improve muscular strength and power
Study NCT03602144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants will receive a protein-based breakfast beverage everyone morning for 42 days.
Study NCT03978572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Continuous Cycling
Description: Exercise intervention designed to improve cardiorespiratory fitness and muscular endurance
Study NCT04606030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioBridge® Collagen Matrix
Description: BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
Study NCT04606030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascularized Lymph Node Transfer (VLNT)
Description: Micro-surgical procedure for vascularized lymph node transfer (VLNT)
Study NCT04606030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vascularized Lymph Node Transfer (VLNT)
Description: Micro-surgical procedure for vascularized lymph node transfer (VLNT)
Study NCT04552847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-octreotide
Description: One intravenous injection of 4 MBq/kg
Study NCT04552847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Patients in part A of the trial will undergo a whole-body PET/CT scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The CT-scan is a low-dose CT that will be acquired for both PET attenuation correction and anatomical information.
Study NCT04552847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Patients in part B of the trial will undergo a whole-body PET/MR scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The MR scan is a fully diagnostic MR requiring intravenous contrast (Dotarem®) injection and Buscopan® administration to minimize bowel movement.
Study NCT02547844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz + emtricitabina + tenofovir
Study NCT02547844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilpivirina + emtricitabina + tenofovir
Study NCT04991415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Study NCT01119417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123
Description: Low dose day: 25 nmol/min, single IV infusion for 15 min.
Study NCT01119417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123
Description: Low dose day: 50 nmol/min, single IV infusion for 15 min
Study NCT01119417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bq123
Description: High dose day: 100 nmol/min, single IV infusion for 15 min.
Study NCT01119417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123
Description: High dose day: 300 nmol/min, single IV infusion for 15 min.
Study NCT01119417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2-3 IV saline infusions for 15 min each.
Study NCT00492583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis (BB-12)
Description: The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).